Johnson Matthey's Fine Chemicals & Catalysts Division’s saw its operating profit rise 5% to £32.4m. The Macfarlan Smith API and intermediate business achieved good sales growth in specialist opiates, despite a rise in manufacturing costs. The Pharmaceutical Materials and Services API manufacturing business had reduced income from amphetamine salts.
Johnson Matthey
Thursday 27 November 2008
Profit rise at Matthey
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment